Ellex to Boost Production of iTrack Microcatheters to 50 Thousand a Year

September 8, 2017: By Jon Swedien
Ellex iTrack microcatheter

Ellex iTrack microcatheter

Ellex Medical Lasers Limited will increase the production of its iTrack canaloplasty microcatheter from 20 thousand annually to 50 thousand, the Australian company announced Sept. 4.

The company is expanding and upgrading its manufacturing facility in Fremont, California. Ellex plans to complete the expansion by July 2018.

In July, Ellex increased production capacity at the Fremont site to 20 thousand units per year from 10 thousand, the company said.

Ellex said it sold about 10 thousand iTrack devices in its 2017 fiscal year that ended June 30.

Meanwhile, Ellex said it has already begun planning for a third production increase that would enable the plant to produce upward of 100 thousand units per year.

In December 2016, the company sold shares to raise $10.3 million to support sales of the iTrack in the US and China.

The Centers for Medicare and Medicaid Services in November 2016 increased the reimbursement available to ASCs purchasing and using the iTrack to $1,747 per procedure in 2017, up from $976 in 2016.

In canaloplasty, the iTrack is inserted into Schlemm’s canal, where it can open or dilate the full 360 degrees of Schlemm’s canal.

Ellex acquired the iTrack in 2014.

Headquartered in Adelaide, Australia, Ellex offers ophthalmic lasers and devices to treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, and age-related macular degeneration.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Imprimis’ Q3-2017 Ophthalmic Revenues Increase 60 Percent, Total $4.9 Million

iVeena Completes Phase I/IIa Study of IVMED-10 for Post-Cataract Inflammation

RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

Bill Link, PhD, Joins LENSAR as Board Chairman

Apellis Prices $150 Million Initial Public Offering

Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

Tivanisiran is Generic Name for Sylentis’ Dry Eye Candidate

Alimera’s Q3-2017 Revenues Increased 18 Percent; Company Sees Expanded Market for Iluvien

Iridex’ Revenues Increase 11 Percent in Q3-2017; 111 Cyclo G6 Systems, 7,800 G6 Probes Shipped

Glaukos’ Net Sales Increase 37 Percent in Q3-2017

Regeneron’s US Eylea Sales Increase 12 Percent in Q3-2017

Second Sight Reports Q3-2017 Net Sales of $1.6 Million, New $122,500 CMS Rate for Argus II

Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

Opternative Sues Warby Parker Over Online Eye Exams

Bausch + Lomb Receives US FDA Approval for Vyzulta for IOP Reduction in Glaucoma Patients

Allergan Plans Cost Cuts, Takes Impairment Charge as Restasis Generics Loom

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022